YRDC protein: A drug target and potential biomarker (G79693)

Target Name: YRDC

NCBI ID: G79693

YRDC

YRDC protein: A drug target and potential biomarker

Yeast Rescue Deficiency (YRDC) protein is a protein that is expressed in various organisms, including humans. It is a member of the YRD family of proteins, which are involved in various cellular processes such as cell signaling, DNA replication, and repair. One of the unique features of YRDC protein is its ability to interact with and modulate the activity of several different proteins, including histone proteins.

The research on YRDC protein has shown that it plays a crucial role in the regulation of gene expression and cell signaling. Several studies have demonstrated that YRDC protein can interact with various histone proteins, including histone H3, histone H2A, and histone H3K9. These interactions can alter the stability and activity of these histones, which in turn can affect the expression of genes that are targeted by these histones.

One of the most interesting aspects of YRDC protein is its potential as a drug target. The ability of YRDC protein to interact with histone proteins makes it an attractive target for small molecules that can modulate its activity. Several studies have shown that YRDC protein is sensitive to small molecules such as inhibitors of the histone-remodeling complex, which is responsible for the regulation of histone stability. Additionally, YRDC protein can also be modulated by small molecules that affect its stability or its interactions with other proteins.

Another potential application of YRDC protein as a drug target is its role as a biomarker. The regulation of gene expression and cell signaling is a critical aspect of many diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. Therefore, the ability to modulate the activity of YRDC protein could be a valuable tool for the development of new treatments for these diseases.

In addition to its potential as a drug target, YRDC protein also has several potential applications as a biomarker. The regulation of gene expression and cell signaling is a critical aspect of many diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. Therefore, the ability to modulate the activity of YRDC protein could be a valuable tool for the development of new treatments for these diseases.

Overall, YRDC protein is a protein that has significant potential as a drug target and biomarker. Its ability to interact with and modulate the activity of several different proteins, including histone proteins, makes it an attractive target for small molecules that can affect its activity. Additionally, its regulation of gene expression and cell signaling makes it a valuable tool for the development of new treatments for various diseases. Further research is needed to fully understand the role of YRDC protein in these processes and to develop new treatments based on its properties.

Protein Name: YrdC N6-threonylcarbamoyltransferase Domain Containing

Functions: Cytoplasmic and mitochondrial threonylcarbamoyl-AMP synthase required for the formation of a threonylcarbamoyl group on adenosine at position 37 (t(6)A37) in tRNAs that read codons beginning with adenine (PubMed:29760464, PubMed:31481669, PubMed:34545459). Catalyzes the conversion of L-threonine, HCO(3)(-)/CO(2) and ATP to give threonylcarbamoyl-AMP (TC-AMP) as the acyladenylate intermediate, with the release of diphosphate (PubMed:29760464). Participates in t(6)A37 formation in cytoplasmic and mitochondrial tRNAs (PubMed:29760464). May regulate the activity of some transporters (By similarity)

The "YRDC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about YRDC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets